A phase III randomized double-blind active-controlled non-inferiority clinical trial to investigate the efficacy and safety of a single injection of Org 36286 (corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation.

Trial Profile

A phase III randomized double-blind active-controlled non-inferiority clinical trial to investigate the efficacy and safety of a single injection of Org 36286 (corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Apr 2017

At a glance

  • Drugs Corifollitropin alfa (Primary) ; Follitropin beta
  • Indications Infertility
  • Focus Registrational; Therapeutic Use
  • Acronyms ENGAGE
  • Sponsors Merck & Co
  • Most Recent Events

    • 19 Oct 2011 Results comparing efficacy outcomes in North America versus European Union presented at the 67th Annual Meeting of the American Society for Reproductive Medicine.
    • 28 Jan 2010 Results presented in a Merck & Co media release.
    • 28 Jan 2010 Updated actual patient numbers from 1509 to 1506 according to a Merck & Co media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top